Selected Immunicum-related Posters & Publications
Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer
Nagasawa, M. et al.
Development of a humanized immunocompetent mouse model to study the relapse vaccine DCP-001
Leitch, C. et al.
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) in combination with anti-CTLA-4 treatment induce complete tumor responses and anti-tumor immune memory in a mouse tumor model
Alex Karlsson-Parra (1, 2), Alexandros Iskantar (1), Di Yu (1) and Chuan Jin (1)
(1) Department of Immunology, Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; (2) Immunicum AB, Stockholm, Sweden
A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma
Magnus Lindskog, MD, PhD; Uppsala University Hospital, Sweden
Karlsson-Parra et al. Phase 1 Trial Evaluating Safety And Efficacy Of Intratumorally Administered Allogeneic Monocyte-Derived Cells (ilixadencel) In Advanced Gastrointestinal Stromal Tumors. ASCO-SITS Clinical Immuno-Oncology Symposium 2020
Durable responses and survival in high risk AML and MDS patients treated with an allogeneic leukemia-derived dendritic cell vaccine
Janssen, L.G. et al.
Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours.
Sommandas, V., Kaur Singh, S., & Manting, E.H.
Rizell et al. Phase I Trial with the Cell-Based Immune Primer Ilixadencel, Alone and Combined with Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol 2019
(link to journal)
Karlsson-Parra et al. Intratumoral administration of pro-inflammatory allogeneic, off-the-shelf, dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect. European Society for Medical Oncology (ESMO) Congress 2018
(link to pdf)
Karlsson-Parra et al. Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharm Res 2018 (link to PubMed)
Rizell et al. Combination treatment of immune primer ilixadencel with standard therapy known to inhibit immunosuppression: a case report. Cholangiocarcinoma Foundation Annual Conference 2018 (link to pdf)
Fotaki et al. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology 2017 (link to PubMed)
Fotaki et al. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology 2017 (link to PubMed)
Fotaki et al. In vitro mode of action of ilixadencel – a cell-based allogeneic immune primer for intratumoral administration. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018 (link to pdf)
Laurell et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer 2017 (link to PubMed)